Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial
This phase 2 trial of pembrolizumab + cabozantinib demonstrated a manageable toxicity profile and promising efficacy as a first-line therapy combination for cisplatin-ineligible patients with mUC.
Authors
- Sumati Gupta (ORCID: https://orcid.org/0000-0001-6271-0831)
- Jad Chahoud (ORCID: https://orcid.org/0000-0002-8435-0264)
- Edward Braun
- Benjamin Louis Maughan (ORCID: https://orcid.org/0000-0002-0010-8551)
- Rohit Jain (ORCID: https://orcid.org/0000-0002-4905-462X)
- Umang Swami (ORCID: https://orcid.org/0000-0003-3518-0411)
- Georges Gebrael (ORCID: https://orcid.org/0000-0002-4085-6415)
- Guru Sonpavde (ORCID: https://orcid.org/0000-0002-1010-9611)
- Jacqueline T. Brown (ORCID: https://orcid.org/0000-0002-1885-0906)
- Kenneth M. Boucher (ORCID: https://orcid.org/0000-0003-2833-0127)
- Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
- Mehmet Asim Bilen
Institutions
- NewYork–Presbyterian Hospital (US)
- Cornell University (US)
- University of Utah (US)
- New York Hospital Queens (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1016/j.euo.2025.04.005
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Exelixis